Find trials
Search tips

C. Albicans during Early Life Predisposes Individuals to Atopy

Overview

About this study

The purpose of this study is to evaluate the contribution of C. albicans to dysbiotic microbial communities of mucosal tissues in pediatric populations. Prospective sampling across multiples tissue sites in a pediatric cohort will be used to assess which tissues are colonized by C. albicans and associated with microbial dysbiosis seen in atopic dermitis.

We hypothesize presence of C. albicans in the microbial communities in early life is associated with atopy. We will assess the presence of C. albicans in the microbial communities of a population of children at-risk for atopic dermatitis compared to healthy controls who do not have an underlying risk for atopy based off family history. In tandem with the collection of human samples, we will utilize mouse models to validate the influence of C. albicans exposure during early life on the systemic immune populations.

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Infants born via vaginal delivery at Mayo Clinic Rochester.
  • Infants must be followed by the Division of Pediatrics with follow-up routine prenatal care to be completed at Baldwin Building.
  • 25 infants will be at high risk for development of atopic dermatitis. High risk for development of atopic dermatitis is determined by an immediate family history (parent or sibling) of one of the following: atopic dermatitis, asthma, allergic rhinitis, or food allergy.
  • 25 infants will be at low risk for development of atopic dermatitis. Low risk for development of atopic dermatitis is determined by an immediate family history (parent or sibling) without the presence of any of the following medical conditions: atopic dermatitis, asthma, allergic rhinitis, or food allergy.
  • No underlying medical conditions at birth including underlying congenital medical conditions.

Exclusion Criteria:

  • Infants born via cesarean section delivery.
  • Infants followed by the Division of Family Medicine with routine follow-up prenatal care to be completed outside of Baldwin Building.
  • Presence of underlying medical conditions at birth including congenital medical conditions.

Eligibility last updated 9/2/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Avni Joshi, M.D., M.S.

Open for enrollment

Contact information:

Melissa Mueller Noreika

(507) 422-5215

Mueller.Melissa2@mayo.edu

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20543630

Mayo Clinic Footer